Kura Oncology
1D
1W
1M
3M
YTD
1Y
5Y
ALL
Why Robinhood?
Robinhood gives you the tools you need to put your money in motion. You can buy or sell Kura Oncology and other ETFs, options, and stocks.About KURA
Kura Oncology, Inc. operates as a clinical-stage biopharmaceutical company, which engages in the research and development of medicines for the treatment of cancer. Its pipeline includes Tipifarnib, which is a Farnesyl transferase inhibitor for HRAS Mutant Solid Tumors, Chronic Myelomonocytic Leukemia, KO-947, which is an ERK inhibitor for MAPK Pathway Tumors, and KO-539, which is a Menin MLL inhibitor for acute leukemias.
CEOTroy E. Wilson
CEOTroy E. Wilson
Employees192
Employees192
HeadquartersSan Diego, California
HeadquartersSan Diego, California
Founded2014
Founded2014
Employees192
Employees192
KURA Key Statistics
Market cap842.37M
Market cap842.37M
Price-Earnings ratio-4.30
Price-Earnings ratio-4.30
Dividend yield—
Dividend yield—
Average volume1.84M
Average volume1.84M
High today$10.13
High today$10.13
Low today$9.10
Low today$9.10
Open price$9.33
Open price$9.33
Volume2.87M
Volume2.87M
52 Week high$19.73
52 Week high$19.73
52 Week low$5.41
52 Week low$5.41
KURA News
Benzinga 1d
Kura Oncology Scores $30 Million Boost As New Leukemia Drug Enters Major TrialKura Oncology, Inc. (NASDAQ:KURA) shares rose Friday after the biotechnology firm confirmed a $30 million milestone payment from its collaboration with Kyowa Ki...
TipRanks 1d
Kura Oncology Receives $30M Milestone PaymentElevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to...
Analyst ratings
87%
of 15 ratingsBuy
86.7%
Hold
13.3%
Sell
0%
People also own
Based on the portfolios of people who own KURA. This list is generated using Robinhood data, and it’s not a recommendation.